Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Chief Medical Officer | November 29, 2024 | December 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Sale · Disposed 4,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2024 Filed Dec 3, 2024 21:18 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | SaleCommon Stock | 4,000 | $3.87 | $15,480.00 |
DisclosureSEC source: 0001437749-24-036551 · rdgdoc.xml · nonDerivative · entry 1 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 21:41 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $26.91 | $0.00 |
DisclosureSEC source: 0001437749-24-028780 · rdgdoc.xml · derivative · entry 1 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-09-06 F1 · derivative.exercise_date: The stock option vests over 2 years, with 50% cliff vesting 1-year after grant date and the remaining 50% cliff vesting 2-years after grant date. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:51 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $22.10 | $0.00 |
DisclosureSEC source: 0001437749-24-018022 · rdgdoc.xml · derivative · entry 1 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-20 F1 · derivative.exercise_date: The stock option vests over four (4) years at a rate of 1/48th each full month. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 13:19 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock Warrant · Derivative | 1,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001437749-24-012643 · rdgdoc.xml · derivative · entry 3 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2024-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.underlying_shares: Form 4 represents exercise for cash of common stock warrants received on January 3, 2024. Holder received one and one-half shares of common stock for each common stock warrant exercised. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 13:19 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 1,500 | $22.00 | $33,000.00 |
DisclosureSEC source: 0001437749-24-012643 · rdgdoc.xml · nonDerivative · entry 1 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Form 4 represents exercise for cash of common stock warrants received on January 3, 2024. Holder received one and one-half shares of common stock for each common stock warrant exercised. Read SEC document |
| January 03, 2024 Filed Apr 22, 2024 13:19 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantCommon Stock Warrant · Derivative | 1,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001437749-24-012643 · rdgdoc.xml · derivative · entry 2 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,500 shares Expires 2024-05-07 F1 · shares: Represents warrants that were originally issued on January 3, 2024 as a distribution to all holders of common shares. Each warrant entitles the holder to purchase one and one-half common shares at an exercise price of $33.00 per warrant. This distribution was exempt from immediate reporting under Section 16. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 22:29 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0001437749-23-027698 · rdgdoc.xml · derivative · entry 1 Kupiec James William · CIK 0001839551 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-10-03 F1 · derivative.exercise_date: The stock option vests over three (3) years at a rate of 1/36th each month. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 20:02 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 2,500 | $24.44 | $61,100.00 |
DisclosureSEC source: 0001069530-22-000039 · certent-form4.xml · nonDerivative · entry 1 Kupiec James William · CIK 0001839551 · Chief Clinical Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.41 to $24.44 per share. The reporting person undertakes to provide to Cassava, any security holder of Cassava or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.